Drug intelligence / Profile preview

MP196

Development stage: Preclinical
Lead developer: OSE Immunotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Suprachoroidal

Overview

MP196 is an investigational monoclonal antibody developed by TcL Pharma. It is one of the company's initial monoclonal antibodies, based on novel approaches to immune system regulation originating from the Institute for Transplantation; Urology and Nephrology (ITUN). MP196 is being developed for applications in organ and tissue transplantation and autoimmune diseases, where it aims to regulate the immune system.

Targets

IL23R (Interleukin-23 Receptor)

Beyond the preview

Go deeper on MP196.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MP196.

Explore the full profile